ArticleFrontiers in oncology2025
Wavelet-enhanced boundary adaptation network for liver hemangioma segmentation in non-contrast CT.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The PAH-AM-PEG-ApoE@siRNA Nanocarrier Delivery System for Polo-like Kinase 1 Inhibition Suppresses Glioma Progression.AAPS PharmSciTech · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver hemangioma segmentation in non-contrast CT images faces significant challenges due to the absence of contrast-enhanced features. This paper introduces WLAU-Net, a novel architecture integrating three key innovations for contrast agent free segmentation. First, our transfer learning framework pre-trains the encoder on venous phase CT images to capture discriminative tumor features, then transfers and freezes these learned weights when processing non-contrast phase data, effectively preventing domain shift. Second, we implement a wavelet transformation module using sym4 wavelet decomposition to split images into four frequency subbands (LL, LH, HL, HH). By selectively amplifying horizontal (HL) and vertical (LH) edge coefficients during reconstruction, we enhance tumor boundary delineation while preserving anatomical context. Third, a local attention mechanism with Gaussian-based adaptive weighting dynamically prioritizes low-intensity tumor regions over high-intensity areas, sharpening focus on subtle boundaries. Experimental results demonstrate WLAU-Net's superiority with a 65.37% Dice score and 96.23% ACC, outperforming state-of-the-art methods including CS-UNet (64.50% Dice, 93.85% ACC) and Swin-UNet (62.34% Dice, 91.15% ACC). Ablation studies reveal critical contributions from each component: enabling all modules (transfer learning, Gaussian attention, and wavelet enhancement) achieves optimal performance, while removing the wavelet module reduces Dice by 1.16% (64.21%) and disabling both Gaussian and wavelet modules decreases ACC by 3.0% (93.24%). Compared to contrast-enhanced methods (92.1% ACC), our approach maintains competitive diagnostic accuracy (96.23% ACC) while eliminating allergic risks, offering a clinically viable alternative for contrast agent sensitive patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.